Assessing immunotoxicity of pharmaceuticals: The need for enhanced testing

Fundamental and Clinical Pharmacology

Volumn 19, Issue 3, 2005, Pages 323-328

  Herzyk, Danuta J ^a   Van Der Laan, Jan Willem ^b   Van Loveren, Henk ^b  

^a GLAXOSMITHKLINE   (United States)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 5; PROSTAGLANDIN D2; SALMETEROL; SALMETEROL XINAFOATE; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

AEROSOL; ANTIBODY RESPONSE; BASOPHIL; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; MEDIATOR RELEASE; MUCOCILIARY CLEARANCE; NONHUMAN; NOTE; PRIORITY JOURNAL; TRICHINELLA SPIRALIS;

EID: 20044393714     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2005.00338.x     Document Type: Note

References (0)